Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) announced that its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.
The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.
Oncology-Focused Biotechnology Company
Sonnet BioTherapeutics is focused on innovating biologic drugs with a proprietary platform for single or bifunctional action.
FHAB Technology
Sonnet's FHAB technology utilizes a fully human single chain antibody fragment for targeting tumor and lymphatic tissue effectively.
Business Combination
The stockholders approved the business combination with Hyperliquid Strategies Inc and Rorschach I LLC at the special meeting.
- Sonnet's FHAB technology offers improved safety and efficacy for immune-modulating biologic drugs by targeting specific tissues.
- The business combination approval indicates a strategic move towards enhancing the company's reach and capabilities.
The approval of the business combination marks a significant milestone for Sonnet BioTherapeutics, positioning them for further advancements in the biotechnology sector.